Cancer vaccine-MUC 1

Drug Profile

Cancer vaccine-MUC 1

Alternative Names: Anti-MUC1 Sp therapeutic vaccine - Vaxil Biotherapeutics; Anti-MUC1 therapeutic cancer vaccine (ImMucin) - Vaxil BioTherapeutics; Cancer vaccine MUC-1; ImMucin; MUC-1; VXL-100

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vaxil BioTherapeutics
  • Developer Hadassah Medical School; Vaxil BioTherapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Breast cancer; Multiple myeloma
  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Israel (Parenteral, Injection)
  • 23 May 2017 Vaxil enters into a manufacturing agreement with BCN Peptides for the cGMP manufacturing of its lead product Cancer vaccine-MUC 1 (VXL100)
  • 22 Mar 2017 Vaxil and Meir Medical Center agree co-develop Cancer vaccine-MUC 1 in Israel for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top